[{"id":"f940d82e-06f2-44db-8afc-37bc80ceac97","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996121","created_at":"2021-08-09T13:53:04.483Z","updated_at":"2025-02-25T17:11:55.305Z","phase":"Phase 1/2","brief_title":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04996121","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" ROS1 • NTRK","pipe":" | ","alterations":" ROS1 fusion • ROS1 positive • NTRK fusion","tags":["ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion • ROS1 positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XZP-5955"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2022-08-30"}]